Electrolysis Percutaneous Therapeutic (EPTE) for Supraspinatus Tendinopathy

Electrolysis Percutaneous Therapeutic (EPTE) for the Management of Supraspinatus Tendinopathy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02196948

Enrollment

Registered

2014-07-22

Start date

2014-07-31

Completion date

2014-12-31

Last updated

2014-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supraspinatus Tendinopathy

Keywords

Supraspinatus, tendinopathy, pain, disability, EPTE

Brief summary

Therapeutic management of supraspinatus tendinopathy is conflicting. There is evidence that eccentric exercise protocols can be effective for this condition. The inclusion of other therapeutic modalities could help to the management of these patients. A new therapeutic approach, called Electrolysis Percutaneous Therapeutic (EPTE) has been clinically developed. The objective of this randomized clinical trial is to determine the effectiveness of the inclusion of EPTE into a eccentric exercise protocol for the management of patients with unilateral supraspinatus tendinopathy

Interventions

OTHERElectrolysis Percutaneous Therapeutic (EPTE)

OTHEREccentric exercise

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Unilateral supraspinatus tendinopathy * Shoulder pain from at least 3 months * Shoulder pain of more than 4 points on a NPRS * Positive findings of supraspinatus tendinopathy on MRI

Exclusion criteria

* bilateral shoulder symptoms * younger than 18 or older than 65 years * history of shoulder fractures or dislocation * cervical radiculopathy * previous interventions with steroid injections * fibromyalgia syndrome * previous history of shoulder or neck surgery * any type of intervention for the neck-shoulder area during the previous year

Design outcomes

Primary

Measure	Time frame	Description
Changes in pain intensity before and after the intervention	Baseline, after 2 weeks of treatment and one week after the last session	A 10-point Numerical Pain Rating Scale (NPRS; 0: no pain, 10: maximum pain) will be used to assess the patients' current level of shoulder pain, and the worst and lowest level of pain experienced in the preceding week in the shoulder area.

Secondary

Measure	Time frame	Description
Changes in disability before and after the intervention	Baseline, after 2 weeks of treatment and one week after the last session	The Disabilities of the Arm, Shoulder and Hand (DASH) will be used to determine the disability induced by shoulder pain

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026